NEW YORK, NY / September 22, 2022 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces that its project been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” will showcase CLS’ data for the use of CLS-014 drug candidate as a platform technology to treat various cancers. CLS has identified a new therapeutic target for the successful anticancer therapy for multiple cancers: tumor- and neutrophils- derived cell-free DNA. Today, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.
The data that will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics.
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.
NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.
Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. (“CLS”) to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) (“Volition”), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.